<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20240722041329&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20240722041329&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 22 Jul 2024 08:13:30 +0000</lastbuilddate>
<pubDate>Sun, 21 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Discovery of deaminase functions by structure-based protein clustering</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39033754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 20:S0092-8674(24)00718-9. doi: 10.1016/j.cell.2024.07.003. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39033754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39033754</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.003>10.1016/j.cell.2024.07.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39033754</guid>
<pubDate>Sun, 21 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiaying Huang</dc:creator>
<dc:creator>Qiupeng Lin</dc:creator>
<dc:creator>Hongyuan Fei</dc:creator>
<dc:creator>Zixin He</dc:creator>
<dc:creator>Hu Xu</dc:creator>
<dc:creator>Yunjia Li</dc:creator>
<dc:creator>Kunli Qu</dc:creator>
<dc:creator>Peng Han</dc:creator>
<dc:creator>Qiang Gao</dc:creator>
<dc:creator>Boshu Li</dc:creator>
<dc:creator>Guanwen Liu</dc:creator>
<dc:creator>Lixiao Zhang</dc:creator>
<dc:creator>Jiacheng Hu</dc:creator>
<dc:creator>Rui Zhang</dc:creator>
<dc:creator>Erwei Zuo</dc:creator>
<dc:creator>Yonglun Luo</dc:creator>
<dc:creator>Yidong Ran</dc:creator>
<dc:creator>Jin-Long Qiu</dc:creator>
<dc:creator>Kevin Tianmeng Zhao</dc:creator>
<dc:creator>Caixia Gao</dc:creator>
<dc:date>2024-07-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery of deaminase functions by structure-based protein clustering</dc:title>
<dc:identifier>pmid:39033754</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.003</dc:identifier>
</item>
<item>
<title>Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39032925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 21;45(28):2463-2467. doi: 10.1093/eurheartj/ehae450.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39032925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39032925</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae450>10.1093/eurheartj/ehae450</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39032925</guid>
<pubDate>Sat, 20 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-07-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves</dc:title>
<dc:identifier>pmid:39032925</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae450</dc:identifier>
</item>
<item>
<title>Functional control of myosin motors in the cardiac cycle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39030271/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>Contraction of the heart is driven by cyclical interactions between myosin and actin filaments powered by ATP hydrolysis. The modular structure of heart muscle and the organ-level synchrony of the heartbeat ensure tight reciprocal coupling between this myosin ATPase cycle and the macroscopic cardiac cycle. The myosin motors respond to the cyclical activation of the actin and myosin filaments to drive the pressure changes that control the inflow and outflow valves of the heart chambers. Opening...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 19. doi: 10.1038/s41569-024-01063-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Contraction of the heart is driven by cyclical interactions between myosin and actin filaments powered by ATP hydrolysis. The modular structure of heart muscle and the organ-level synchrony of the heartbeat ensure tight reciprocal coupling between this myosin ATPase cycle and the macroscopic cardiac cycle. The myosin motors respond to the cyclical activation of the actin and myosin filaments to drive the pressure changes that control the inflow and outflow valves of the heart chambers. Opening and closing of the valves in turn switches the myosin motors between roughly isometric and roughly isotonic contraction modes. Peak filament stress in the heart is much smaller than in fully activated skeletal muscle, although the myosin filaments in the two muscle types have the same number of myosin motors. Calculations indicate that only ~5% of the myosin motors in the heart are needed to generate peak systolic pressure, although many more motors are needed to drive ejection. Tight regulation of the number of active motors is essential for the efficient functioning of the healthy heart - this control is commonly disrupted by gene variants associated with inherited heart disease, and its restoration might be a useful end point in the development of novel therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39030271/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39030271</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01063-5>10.1038/s41569-024-01063-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39030271</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Malcolm Irving</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Functional control of myosin motors in the cardiac cycle</dc:title>
<dc:identifier>pmid:39030271</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01063-5</dc:identifier>
</item>
<item>
<title>Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39030270/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>For more than 60 years, humans have travelled into space. Until now, the majority of astronauts have been professional, government agency astronauts selected, in part, for their superlative physical fitness and the absence of disease. Commercial spaceflight is now becoming accessible to members of the public, many of whom would previously have been excluded owing to unsatisfactory fitness or the presence of cardiorespiratory diseases. While data exist on the effects of gravitational and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 19. doi: 10.1038/s41569-024-01047-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For more than 60 years, humans have travelled into space. Until now, the majority of astronauts have been professional, government agency astronauts selected, in part, for their superlative physical fitness and the absence of disease. Commercial spaceflight is now becoming accessible to members of the public, many of whom would previously have been excluded owing to unsatisfactory fitness or the presence of cardiorespiratory diseases. While data exist on the effects of gravitational and acceleration (G) forces on human physiology, data on the effects of the aerospace environment in unselected members of the public, and particularly in those with clinically significant pathology, are limited. Although short in duration, these high acceleration forces can potentially either impair the experience or, more seriously, pose a risk to health in some individuals. Rather than expose individuals with existing pathology to G forces to collect data, computational modelling might be useful to predict the nature and severity of cardiovascular diseases that are of sufficient risk to restrict access, require modification, or suggest further investigation or training before flight. In this Review, we explore state-of-the-art, zero-dimensional, compartmentalized models of human cardiovascular pathophysiology that can be used to simulate the effects of acceleration forces, homeostatic regulation and ventilation-perfusion matching, using data generated by long-arm centrifuge facilities of the US National Aeronautics and Space Administration and the European Space Agency to risk stratify individuals and help to improve safety in commercial suborbital spaceflight.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39030270/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39030270</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01047-5>10.1038/s41569-024-01047-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39030270</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul D Morris</dc:creator>
<dc:creator>Ryan A Anderton</dc:creator>
<dc:creator>Karina Marshall-Goebel</dc:creator>
<dc:creator>Joseph K Britton</dc:creator>
<dc:creator>Stuart M C Lee</dc:creator>
<dc:creator>Nicolas P Smith</dc:creator>
<dc:creator>Frans N van de Vosse</dc:creator>
<dc:creator>Karen M Ong</dc:creator>
<dc:creator>Tom A Newman</dc:creator>
<dc:creator>Daniel J Taylor</dc:creator>
<dc:creator>Tim Chico</dc:creator>
<dc:creator>Julian P Gunn</dc:creator>
<dc:creator>Andrew J Narracott</dc:creator>
<dc:creator>D Rod Hose</dc:creator>
<dc:creator>Ian Halliday</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight</dc:title>
<dc:identifier>pmid:39030270</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01047-5</dc:identifier>
</item>
<item>
<title>Manuscript submission to European Heart Journal: easier than ever</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39028843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae260. doi: 10.1093/eurheartj/ehae260. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39028843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39028843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae260>10.1093/eurheartj/ehae260</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39028843</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Alexandra Frances Kavaney</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Manuscript submission to European Heart Journal: easier than ever</dc:title>
<dc:identifier>pmid:39028843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae260</dc:identifier>
</item>
<item>
<title>Periprocedural myocardial infarction: thresholds of (in)significance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39028751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae451. doi: 10.1093/eurheartj/ehae451. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39028751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39028751</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae451>10.1093/eurheartj/ehae451</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39028751</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Periprocedural myocardial infarction: thresholds of (in)significance</dc:title>
<dc:identifier>pmid:39028751</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae451</dc:identifier>
</item>
<item>
<title>Genetic testing in early-onset atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39028637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae298. doi: 10.1093/eurheartj/ehae298. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%-11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research-mechanistic, translational, and clinical-is urgently needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39028637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39028637</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae298>10.1093/eurheartj/ehae298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39028637</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Sean J Jurgens</dc:creator>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Ingrid E Christophersen</dc:creator>
<dc:creator>Michiel Rienstra</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Elizabeth M McNally</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Heidi L Rehm</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Dan M Roden</dc:creator>
<dc:creator>M Benjamin Shoemaker</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Genetic testing in early-onset atrial fibrillation</dc:title>
<dc:identifier>pmid:39028637</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae298</dc:identifier>
</item>
<item>
<title>Pulmonary artery pressure-guided heart failure care: the setting matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae441. doi: 10.1093/eurheartj/ehae441. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39027970</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae441>10.1093/eurheartj/ehae441</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027970</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefan Störk</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pressure-guided heart failure care: the setting matters</dc:title>
<dc:identifier>pmid:39027970</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae441</dc:identifier>
</item>
<item>
<title>Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027969/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae424. doi: 10.1093/eurheartj/ehae424. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39027969</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae424>10.1093/eurheartj/ehae424</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027969</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Aschermann</dc:creator>
<dc:creator>Jean Jacques Monsuez</dc:creator>
<dc:creator>Goksel Cinier</dc:creator>
<dc:creator>Editors Network of the National Societies of Cardiology Journals, European Society of Cardiology</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals</dc:title>
<dc:identifier>pmid:39027969</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae424</dc:identifier>
</item>
<item>
<title>Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae445. doi: 10.1093/eurheartj/ehae445. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39027965</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae445>10.1093/eurheartj/ehae445</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027965</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Alfonso Jurado-Román</dc:creator>
<dc:creator>Pilar Agudo-Quílez</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance</dc:title>
<dc:identifier>pmid:39027965</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae445</dc:identifier>
</item>
<item>
<title>Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027946/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae398. doi: 10.1093/eurheartj/ehae398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the efficacy and safety of catheter-based LAAC, largely compared with vitamin K antagonists. LAA device iterations, advances in pre- and peri-procedural imaging, and implantation techniques continue to increase the efficacy and safety of LAAC. More data about efficacy and safety of LAAC have been collected, and several randomized clinical trials are currently underway to compare LAAC with best medical care (including non-vitamin K antagonist oral anticoagulants) in different clinical settings. Surgical LAAC in patients with AF undergoing cardiac surgery reduced the risk of stroke on background of anticoagulation therapy in the LAAOS III study. In this review, we describe the rapidly evolving field of LAAC and discuss recent clinical data, ongoing studies, open questions, and current limitations of LAAC.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027946/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39027946</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae398>10.1093/eurheartj/ehae398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027946</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives</dc:title>
<dc:identifier>pmid:39027946</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae398</dc:identifier>
</item>
<item>
<title>A New linc(-RNA) Between NFAT/MEF2 and Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39024397/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 19;135(3):450-452. doi: 10.1161/CIRCRESAHA.124.324794. Epub 2024 Jul 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39024397/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39024397</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324794>10.1161/CIRCRESAHA.124.324794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39024397</guid>
<pubDate>Thu, 18 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chen Gao</dc:creator>
<dc:creator>Yibin Wang</dc:creator>
<dc:date>2024-07-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>A New linc(-RNA) Between NFAT/MEF2 and Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:39024397</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324794</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39024395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 19;135(3):414-415. doi: 10.1161/RES.0000000000000683. Epub 2024 Jul 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39024395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39024395</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000683>10.1161/RES.0000000000000683</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39024395</guid>
<pubDate>Thu, 18 Jul 2024 06:00:00 -0400</pubDate>
<dc:date>2024-07-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39024395</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000683</dc:identifier>
</item>
<item>
<title>Dietary patterns to promote cardiometabolic health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39020052/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the risk of cardiovascular events. Furthermore, low sodium intake can be particularly beneficial for patients with hypertension. Carbohydrate restriction, with an emphasis on including high-quality carbohydrates and limiting refined starches and foods and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 17. doi: 10.1038/s41569-024-01061-7. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Multiple professional societies recommend the Mediterranean and/or Dietary Approaches to Stop Hypertension dietary patterns in their cardiovascular disease prevention guidelines because these diets can improve cardiometabolic health and reduce the risk of cardiovascular events. Furthermore, low sodium intake can be particularly beneficial for patients with hypertension. Carbohydrate restriction, with an emphasis on including high-quality carbohydrates and limiting refined starches and foods and beverages with added sugars, can promote weight loss and cardiometabolic benefits in the short term, compared with higher carbohydrate intake. Evidence is lacking for sustained, long-term effects of low carbohydrate and very low carbohydrate intake on cardiometabolic risk and cardiovascular outcomes. Time-restricted eating, in the context of an overall healthy dietary pattern, can promote cardiometabolic health by aligning food intake with the circadian rhythm, although its effect on hard clinical outcomes remains to be proven. Although there is no one dietary pattern that is appropriate for all patients, engaging in shared decision-making with patients, utilizing behaviour-change principles and engaging members of the health-care team, such as registered dietitian nutritionists, can lead to substantial improvement in the lifestyle and overall health trajectory of a patient. Emphasizing the similarities, rather than differences, of recommended dietary patterns, which include an emphasis on vegetables, fruits, legumes, nuts, whole grains and minimally processed protein foods, such as fatty fish or plant-based proteins, can simplify the process for both patients and clinicians alike.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39020052/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39020052</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01061-7>10.1038/s41569-024-01061-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39020052</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Robert J Ostfeld</dc:creator>
<dc:creator>Carol F Kirkpatrick</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Dietary patterns to promote cardiometabolic health</dc:title>
<dc:identifier>pmid:39020052</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01061-7</dc:identifier>
</item>
<item>
<title>Septal Ablation to Treat Subaortic Dynamic Obstruction Following Transcatheter Aortic Valve Implantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>Dynamic obstruction of the left ventricle is an unusual complication that can occur after aortic valve replacement. It is important to be aware of this pathology as it requires different management than normal complications and can rapidly lead to death. We present a case of successful resolution following transcatheter aortic valve implantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):411-415. doi: 10.1016/j.jacc.2024.05.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dynamic obstruction of the left ventricle is an unusual complication that can occur after aortic valve replacement. It is important to be aware of this pathology as it requires different management than normal complications and can rapidly lead to death. We present a case of successful resolution following transcatheter aortic valve implantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019535</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.032>10.1016/j.jacc.2024.05.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019535</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lidia María Carrillo Mora</dc:creator>
<dc:creator>José Javier Tercero Fajardo</dc:creator>
<dc:creator>Diana Milena Cruz Sepúlveda</dc:creator>
<dc:creator>Juan Ramón Gimeno Blanes</dc:creator>
<dc:creator>Juan García De Lara</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Septal Ablation to Treat Subaortic Dynamic Obstruction Following Transcatheter Aortic Valve Implantation</dc:title>
<dc:identifier>pmid:39019535</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.032</dc:identifier>
</item>
<item>
<title>Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019534/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):408-410. doi: 10.1016/j.jacc.2024.05.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019534/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019534</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.028>10.1016/j.jacc.2024.05.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019534</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucas L Marinho</dc:creator>
<dc:creator>Brendan M Everett</dc:creator>
<dc:creator>Aaron W Aday</dc:creator>
<dc:creator>Frank L J Visseren</dc:creator>
<dc:creator>Jean G MacFadyen</dc:creator>
<dc:creator>Elaine Zaharris</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Raul D Santos</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Jean-Charles Fruchart</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Aruna Das Pradhan</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT</dc:title>
<dc:identifier>pmid:39019534</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.028</dc:identifier>
</item>
<item>
<title>Sutureless Valves, a "Wireless" Option for Patients With Aortic Valve Disease: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019533/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>Transcatheter technologies triggered the recent revision of the guidelines that progressively widened the indications for the treatment of aortic stenosis. On the surgical realm, a technology avoiding the need for sutures to anchor the prosthesis to the aortic annulus has been developed with the aim to reduce the duration of cardiopulmonary bypass and simplify the process of valve implantation. In addition to a transcatheter aortic valve replacement (TAVR)-like stent that exerts a radial force,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):382-407. doi: 10.1016/j.jacc.2024.05.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcatheter technologies triggered the recent revision of the guidelines that progressively widened the indications for the treatment of aortic stenosis. On the surgical realm, a technology avoiding the need for sutures to anchor the prosthesis to the aortic annulus has been developed with the aim to reduce the duration of cardiopulmonary bypass and simplify the process of valve implantation. In addition to a transcatheter aortic valve replacement (TAVR)-like stent that exerts a radial force, these so-called "rapid deployment valves" or "sutureless valves" for aortic valve replacement also have cuffs to improve sealing and reduce the risk of paravalvular leak. Despite promising, the actual advantage of sutureless valves over traditional surgical procedures (surgical aortic valve replacement) or TAVR is still debated. This review summarizes the current comparative evidence reporting outcomes of "sutureless valves" for aortic valve replacement to TAVR and surgical aortic valve replacement in the treatment of aortic valve stenosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019533/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019533</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.031>10.1016/j.jacc.2024.05.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019533</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Cristiano Spadaccio</dc:creator>
<dc:creator>Antonio Nenna</dc:creator>
<dc:creator>Angelo Pisani</dc:creator>
<dc:creator>Grzegorz Laskawski</dc:creator>
<dc:creator>Francesco Nappi</dc:creator>
<dc:creator>Marc R Moon</dc:creator>
<dc:creator>Fausto Biancari</dc:creator>
<dc:creator>Arminder S Jassar</dc:creator>
<dc:creator>Kevin L Greason</dc:creator>
<dc:creator>Malakh L Shrestha</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>David Rose</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sutureless Valves, a "Wireless" Option for Patients With Aortic Valve Disease: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:39019533</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.031</dc:identifier>
</item>
<item>
<title>Reluctance: The Ongoing Reality of Intravascular Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):379-381. doi: 10.1016/j.jacc.2024.05.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019532</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.026>10.1016/j.jacc.2024.05.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019532</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Luis Gruberg</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reluctance: The Ongoing Reality of Intravascular Imaging</dc:title>
<dc:identifier>pmid:39019532</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.026</dc:identifier>
</item>
<item>
<title>Anticoagulants in Subclinical Atrial Fibrillation: Beginning to Define the Treatment Paradigm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019531/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):365-367. doi: 10.1016/j.jacc.2024.05.015. Epub 2024 May 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019531/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019531</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.015>10.1016/j.jacc.2024.05.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019531</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sachin J Shah</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anticoagulants in Subclinical Atrial Fibrillation: Beginning to Define the Treatment Paradigm</dc:title>
<dc:identifier>pmid:39019531</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.015</dc:identifier>
</item>
<item>
<title>Apixaban vs Aspirin According to CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA(2)DS(2)-VASc score >;4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA(2)DS(2)-VASc score &lt;4. A substantial intermediate group (CHA(2)DS(2)-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):354-364. doi: 10.1016/j.jacc.2024.05.002. Epub 2024 May 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To help inform decision making, the authors evaluated the efficacy and safety of apixaban according to baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a subgroup analysis according to baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score and assessed both the relative and absolute differences in stroke/SE and major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc scores were &lt;4 in 1,578 (39.4%) patients, 4 in 1,349 (33.6%), and >;4 in 1,085 (27.0%). For patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc >;4, the rate of stroke was 0.98%/year with apixaban and 2.25%/year with aspirin; compared with aspirin, apixaban prevented 1.28 (95% CI: 0.43-2.12) strokes/SE per 100 patient-years and caused 0.68 (95% CI: -0.23 to 1.57) major bleeds. For CHA<sub>2</sub>DS<sub>2</sub>-VASc &lt;4, the stroke/SE rate was 0.85%/year with apixaban and 0.97%/year with aspirin. Apixaban prevented 0.12 (95% CI: -0.38 to 0.62) strokes/SE per 100 patient-years and caused 0.33 (95% CI: -0.27 to 0.92) major bleeds. For patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc =4, apixaban prevented 0.32 (95% CI: -0.16 to 0.79) strokes/SE per 100 patient-years and caused 0.28 (95% CI: -0.30 to 0.86) major bleeds.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA<sub>2</sub>DS<sub>2</sub>-VASc score >;4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score &lt;4. A substantial intermediate group (CHA<sub>2</sub>DS<sub>2</sub>-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; NCT01938248).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019530</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.002>10.1016/j.jacc.2024.05.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019530</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>William F McIntyre</dc:creator>
<dc:creator>Marco Alings</dc:creator>
<dc:creator>Thenmozhi Mani</dc:creator>
<dc:creator>Chinthanie Ramasundarahettige</dc:creator>
<dc:creator>Lena Rivard</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>David H Birnie</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Guy Amit</dc:creator>
<dc:creator>Peter Leong-Sit</dc:creator>
<dc:creator>Claus Rinne</dc:creator>
<dc:creator>Gabor Z Duray</dc:creator>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>Stefan H Hohnloser</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:creator>Juan Benezet-Mazuecos</dc:creator>
<dc:creator>Jens Cosedis Nielsen</dc:creator>
<dc:creator>Christian Sticherling</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Cecilia Linde</dc:creator>
<dc:creator>Joseph Kautzner</dc:creator>
<dc:creator>Philippe Mabo</dc:creator>
<dc:creator>Georges H Mairesse</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Apixaban vs Aspirin According to CHA&lt;sub>;2&lt;/sub>;DS&lt;sub>;2&lt;/sub>;-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA</dc:title>
<dc:identifier>pmid:39019530</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.002</dc:identifier>
</item>
<item>
<title>Does REVIVED Complete You?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39019529/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240722041329&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 23;84(4):351-353. doi: 10.1016/j.jacc.2024.05.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39019529/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240722041329&v=2.18.0.post9+e462414">39019529</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.024>10.1016/j.jacc.2024.05.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39019529</guid>
<pubDate>Wed, 17 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Fiyyaz Ahmed-Jushuf</dc:creator>
<dc:creator>Shayna Chotai</dc:creator>
<dc:creator>Rasha K Al-Lamee</dc:creator>
<dc:date>2024-07-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Does REVIVED Complete You?</dc:title>
<dc:identifier>pmid:39019529</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.024</dc:identifier>
</item>





























</channel>
</rss>